Status of work
In April, AOTMiT begins work on orders from the Minister of Health:
- Keytruda (pembrolizumab) for the treatment of patients with squamous cell carcinoma of the head and neck
- Imfinzi (durvalumab) for the treatment of patients with urothelial carcinoma
- Tezspire (tezepelumab) for the treatment of patients with rhinosinusitis with nasal polyps
The listed order is available on the AOTMiT Public Information Bulletin.